{
  "metadata": {
    "input_documents": [
      "ADA_Type2Diabetes_Guideline_2025.pdf",
      "GLP1RA_Cardiovascular_Outcomes_Summary.pdf",
      "SGLT2_Inhibitors_CKD_Type2Diabetes_Guidelines_Review.pdf",
      "Patient_Lifestyle_Education_Protocol_Type2Diabetes.pdf"
    ],
    "persona": "Primary Care Physician",
    "job_to_be_done": "Summarize the latest evidence-based best practices on managing newly diagnosed Type 2 diabetes patients, and develop a stepwise treatment plan tailored to patient comorbidities that can be applied in a primary care setting.",
    "processing_timestamp": "2025-07-28T20:12:00.000000"
  },
  "extracted_sections": [
    {
      "document": "ADA_Type2Diabetes_Guideline_2025.pdf",
      "section_title": "Initial Management: Lifestyle interventions and Metformin initiation",
      "importance_rank": 1,
      "page_number": 3
    },
    {
      "document": "SGLT2_Inhibitors_CKD_Type2Diabetes_Guidelines_Review.pdf",
      "section_title": "SGLT2 Inhibitors in CKD and Cardiovascular Risk Reduction",
      "importance_rank": 2,
      "page_number": 2
    },
    {
      "document": "GLP1RA_Cardiovascular_Outcomes_Summary.pdf",
      "section_title": "GLP-1 RA Benefits in Atherosclerotic Cardiovascular Disease (ASCVD)",
      "importance_rank": 3,
      "page_number": 1
    },
    {
      "document": "Patient_Lifestyle_Education_Protocol_Type2Diabetes.pdf",
      "section_title": "Structured Patient Education and Self-Management Strategies",
      "importance_rank": 4,
      "page_number": 1
    },
    {
      "document": "ADA_Type2Diabetes_Guideline_2025.pdf",
      "section_title": "Individualized Treatment Algorithm Based on Comorbidities",
      "importance_rank": 5,
      "page_number": 5
    }
  ],
  "subsection_analysis": [
    {
      "document": "ADA_Type2Diabetes_Guideline_2025.pdf",
      "refined_text": "The ADA 2025 guideline emphasizes early intervention using lifestyle modification and metformin as the first-line treatment for newly diagnosed patients. It highlights the importance of nutrition, physical activity, and weight loss targets for glycemic control.",
      "page_number": 3
    },
    {
      "document": "SGLT2_Inhibitors_CKD_Type2Diabetes_Guidelines_Review.pdf",
      "refined_text": "SGLT2 inhibitors are recommended for patients with CKD or high cardiovascular risk, as they provide renal protection and reduce major cardiovascular events. Benefits are independent of glycemic control.",
      "page_number": 2
    },
    {
      "document": "GLP1RA_Cardiovascular_Outcomes_Summary.pdf",
      "refined_text": "GLP-1 receptor agonists significantly reduce major adverse cardiovascular events in patients with established ASCVD. They are especially useful in patients where weight loss and cardiovascular protection are priorities.",
      "page_number": 1
    },
    {
      "document": "Patient_Lifestyle_Education_Protocol_Type2Diabetes.pdf",
      "refined_text": "Effective patient education includes goal-setting, dietary coaching, exercise planning, and self-monitoring. Engaging patients early through structured programs improves long-term adherence and glycemic outcomes.",
      "page_number": 1
    },
    {
      "document": "ADA_Type2Diabetes_Guideline_2025.pdf",
      "refined_text": "Treatment should be tailored based on comorbidities. For patients with ASCVD, GLP-1 RAs are prioritized; SGLT2 inhibitors are preferred for HF or CKD. Dual or triple therapy may be initiated earlier in certain populations.",
      "page_number": 5
    }
  ]
}
